Pharming Group N.V. PHAR

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating income $25.8M-$8.6M-$5.4M$18.2M$13.6M$76.3M$68.2M—
Net income $2.5M-$11.8M-$10.5M$13.7M$16.0M$37.7M$40.6M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets $500.0M$400.0M$462.9M$425.8M$397.3M$418.5M$255.9M—
Total equity $277.1M$221.1M$218.8M$204.6M$192.9M$183.4M$117.4M$64.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001828316-26-000019.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total current assets
  • Receivables
  • Depreciation and amortisation
  • Total equity
Total current assets, Receivables, Depreciation and amortisation, Total equity by fiscal year, in US dollars The same figures are in the table below this chart. 0 100M 200M 300M Total equity, FY2018: 64.1M Total equity, FY2019: 117.4M Total equity, FY2020: 183.4M Total equity, FY2021: 192.9M Total equity, FY2022: 204.6M Total equity, FY2023: 218.8M Total equity, FY2024: 221.1M Total equity, FY2025: 277.1M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total current assets — — — — — — — —
Receivables — — — — — — — —
Depreciation and amortisation — — — — — — — —
Total equity $64.1M $117.4M $183.4M $192.9M $204.6M $218.8M $221.1M $277.1M

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%